MediWound (NASDAQ:MDWD) Issues Earnings Results, Beats Estimates By $0.23 EPS

MediWound (NASDAQ:MDWD) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.23, RTT News reports. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. The firm had revenue of $5.84 million for the quarter, compared to the consensus estimate of $5.79 million. During the same quarter in the prior year, the business earned ($0.19) earnings per share.

MediWound Stock Down 5.1 %

MDWD stock opened at $18.28 on Thursday. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The business has a 50 day moving average price of $18.15 and a 200 day moving average price of $17.60. The stock has a market cap of $197.17 million, a price-to-earnings ratio of -6.30 and a beta of 0.82.

Wall Street Analyst Weigh In

MDWD has been the topic of a number of recent analyst reports. Craig Hallum began coverage on MediWound in a research report on Friday, February 28th. They set a “buy” rating and a $39.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of MediWound in a report on Friday, January 10th.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.